Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIPRIVAN vs AMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in intensive care units,Monitored anesthesia care (MAC) sedation,Treatment of refractory status epilepticus (off-label),Procedural sedation (off-label)
Induction of general anesthesia,Maintenance of anesthesia (as part of balanced anesthesia),Procedural sedation (off-label),Rapid sequence intubation (RSI) (off-label)
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Primarily hepatic conjugation to inactive metabolites (propofol glucuronide), with minor metabolism via CYP2B6 and CYP2C9 to 4-hydroxypropofol.
Primarily hepatic via hydrolysis by esterases to inactive metabolites (carboxylic acid and ethanol); also undergoes glucuronidation.
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
95-99% bound, primarily to albumin.
97–98% bound; Primary binding to albumin; Reduced binding in neonates and hepatic/renal disease.
2-10 L/kg (large Vd indicating extensive tissue distribution).
Vd: 2.5–4.5 L/kg; Large Vd indicates extensive tissue distribution (highly lipophilic).
Intravenous: 100%; not available orally due to extensive first-pass metabolism.
IV: 100%; IM: >90%; Rectal: ~50% (variable).
No adjustment required; propofol is not significantly renally eliminated.
No adjustment required; pharmacokinetics unchanged in renal impairment.
No specific Child-Pugh based guidelines; use lower doses due to impaired clearance, especially in cirrhosis.
No specific guidelines; use with caution in severe hepatic impairment due to potential for decreased clearance.
Induction: 2.5-3.5 mg/kg IV bolus; maintenance: 125-300 mcg/kg/min IV infusion. Not approved for ICU sedation in <16 years.
3-5 mg/kg IV bolus for induction in children; lower doses may be sufficient.
Reduce induction dose to 1-1.5 mg/kg IV bolus and maintenance infusion to 20-50 mcg/kg/min IV due to increased sensitivity and decreased clearance.
Reduce dose to 0.15-0.3 mg/kg IV bolus due to increased sensitivity and decreased clearance.
Propofol should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Patients should be continuously monitored for early signs of hypotension, bradycardia, apnea, airway obstruction, and oxygen desaturation. For sedation of intubated, mechanically ventilated patients in the ICU, propofol should be used with caution in patients with increased intracranial pressure or impaired cerebral circulation.
None
Risk of hypotension and bradycardia, especially in elderly or hypovolemic patients,Respiratory depression and apnea requiring airway management,Propofol infusion syndrome (PRIS): metabolic acidosis, rhabdomyolysis, renal failure, cardiac failure, especially with prolonged high-dose infusions,Hypertriglyceridemia; monitor lipids with prolonged use,Risk of pancreatitis,Use with caution in patients with epilepsy; may increase seizure risk during withdrawal,May cause green discoloration of urine, hair, or nails
Suppresses adrenal steroidogenesis via reversible inhibition of 11-beta-hydroxylase (cortisol and aldosterone synthesis) – risk of adrenal insufficiency, especially with prolonged infusion or multiple doses,May cause myoclonus (involuntary muscle movements) during induction,Can produce hypotension less frequently than other induction agents, but still possible,Use caution in patients with adrenal suppression, sepsis, or hepatic impairment,May cause pain on injection (use large vein or consider pretreatment)
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, egg products, soybeans, or soy products (due to lipid vehicle),Patients with severe lipid metabolism disorders (e.g., hyperlipidemia),Not recommended for general anesthesia in patients with increased intracranial pressure or impaired cerebral circulation unless benefits outweigh risks
Known hypersensitivity to etomidate or any component of the formulation,Patients with known adrenal insufficiency (relative contraindication due to potential for further suppression)
No specific food interactions; however, propofol emulsion contains soybean oil and egg lecithin, so avoid in patients with egg or soy allergies. The emulsion can be contaminated if bottle is reused; discard after single use. No dietary restrictions required for administration.
None known. However, because etomidate is administered intravenously in a fasting state prior to procedures, food intake is restricted per standard pre-procedural fasting guidelines (typically NPO for 6-8 hours).
Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third trimesters, propofol crosses the placenta and may cause neonatal respiratory depression and neurobehavioral depression. Risk of fetal acidosis and bradycardia. No major teratogenic effects reported in human studies, but limited data.
Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: May cause fetal CNS depression, hypotonia, and respiratory depression with chronic use. Avoid in pregnancy unless benefit outweighs risk.
Propofol is excreted into breast milk in low concentrations. M/P ratio not established. Due to low oral bioavailability, risk to infant is minimal. However, caution is advised due to potential CNS depression in neonates. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration.
Excreted in breast milk; M/P ratio 0.5-0.8. Potential for infant sedation and respiratory depression. Caution advised; monitor infant for drowsiness and feeding difficulties. Consider alternative therapies.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, particularly in the third trimester. No specific dose adjustment guidelines; clinical response and patient condition determine dosing. Reduced doses may be required due to increased sensitivity to propofol in pregnancy.
No standard dose adjustment recommended; however, increased clearance during pregnancy may necessitate higher doses for efficacy. Monitor therapeutic response and adjust as needed. Avoid use in first trimester if possible.
DIPRIVAN (propofol) causes pain on injection, especially in small veins; pretreatment with lidocaine or use of a larger vein can mitigate. It is formulated as a lipid emulsion containing soybean oil and egg lecithin, thus contraindicated in patients with egg or soybean allergies. Propofol can cause profound hypotension and respiratory depression; ensure airway equipment and vasopressors are immediately available. The infusion syndrome (PRIS) is rare but lethal, characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure; avoid prolonged high-dose infusions (>5 mg/kg/hr for >48 hours).
Amidate (etomidate) is an ultra-short acting non-barbiturate hypnotic used for induction of anesthesia and for procedural sedation. Key pearls: (1) Single dose causes adrenal suppression via 11β-hydroxylase inhibition; avoid continuous infusion or repeated doses. (2) Preferred for hemodynamically unstable patients due to minimal cardiovascular depression. (3) High incidence of myoclonus and pain on injection; pretreat with opioid or benzodiazepine to reduce myoclonus. (4) Contraindicated in porphyria. (5) Rapid onset (30-60 sec) and short duration (3-5 min) limit use to induction only.
You will be monitored continuously during and after administration due to risk of low blood pressure and slowed breathing.,You may feel a burning or stinging sensation at the injection site; inform your healthcare provider if it persists.,Do not drive or operate machinery for at least 24 hours after receiving propofol due to residual sedation.,Inform your medical team if you have allergies to eggs, soy, or sesame seeds.,Propofol is not intended for home use; it is only administered in a supervised medical setting.
This medication is given only by a healthcare professional in a hospital or clinic setting.,You may experience involuntary muscle movements (myoclonus) or pain at the injection site.,Tell your doctor if you have adrenal gland problems, porphyria, or if you are pregnant or breastfeeding.,The effects are short-lived; you will be monitored closely during and after administration.,Do not drive or operate machinery for at least 24 hours after receiving this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIPRIVAN vs AMIDATE, answered by our medical review team.
DIPRIVAN is a General Anesthetic that works by Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.. AMIDATE is a General Anesthetic that works by AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIPRIVAN and AMIDATE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIPRIVAN is: Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.. The standard adult dose of AMIDATE is: 0.2-0.6 mg/kg IV bolus for induction of anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIPRIVAN and AMIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIPRIVAN is classified as Category C. Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third tr. AMIDATE is classified as Category C. Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.